An additional possible benefit for targeting through vimentin recognition is that a unique extracellular deposition for vimentin has now been shown to mark the stroma of prostate cancer lesions but not prostate hyperplasia or normal prostate epithelial tissue [45]. The gene discussed is VIM; the disease is prostate cancer.